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Abstract: Autophagy is a tightly regulated catabolic process that facilitates nutrient recycling from
damaged organelles and other cellular components through lysosomal degradation. Deregulation
of this process has been associated with the development of several pathophysiological processes,
such as cancer and neurodegenerative diseases. In cancer, autophagy has opposing roles, being either
cytoprotective or cytotoxic. Thus, deciphering the role of autophagy in each tumor context is crucial.
Moreover, autophagy has been shown to contribute to chemoresistance in some patients. In this
regard, autophagy modulation has recently emerged as a promising therapeutic strategy for the
treatment and chemosensitization of tumors, and has already demonstrated positive clinical results
in patients. In this review, the dual role of autophagy during carcinogenesis is discussed and current
therapeutic strategies aimed at targeting autophagy for the treatment of cancer, both under preclinical
and clinical development, are presented. The use of autophagy modulators in combination therapies,
in order to overcome drug resistance during cancer treatment, is also discussed as well as the potential
challenges and limitations for the use of these novel therapeutic strategies in the clinic.
Keywords: autophagy; anticancer therapy; autophagy inhibitors; autophagic cell death;
chemoresistance; chemosensitization
1. Introduction
Cellular homeostasis is crucial for cell survival and refers to all processes involved in the
maintenance of an internal steady state at the level of the cell. Autophagy is one of the main catabolic
mechanisms that contributes to cellular homeostasis, through the degradation and recycling of
cytoplasmic components and organelles in the lysosomes [1,2]. This process confers the ability to adapt
to environmental stresses, preventing cellular damage, and promoting cell survival, even in starving
conditions, thus having a main physiologic cytoprotective role. It is a process tightly regulated and its
dysfunction has been related to several pathologies, such as neurodegeneration, cancer, or aging [3].
Hence, autophagy modulation is emerging as a promising new therapeutic strategy to treat these
malignancies [4]. Indeed, more than 120 clinical trials related to the process of autophagy were initiated
to date. The majority of those target autophagy for cancer treatment, already showing promising
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results, for instance, using chloroquine or hydroxychloroquine as single agents or in combination
therapies [5,6]. Nevertheless, the role of autophagy in cancer is somewhat controversial. Cytotoxic or
cytoprotective roles have been reported depending on the cellular context [7]. Therefore, the deep
understanding of autophagy regulation and the identification of its role in each cellular context is
crucial for the selection of an appropriate therapeutic intervention involving autophagy modulation
in cancer.
In this review, the molecular mechanisms that regulate autophagy and the dual role of autophagy
in cancer are presented and discussed. Moreover, current strategies targeting autophagy for cancer
treatment are summarized, highlighting combination therapies involving autophagy modulators that
can sensitize cancer cells to conventional therapies, thus being able to overcome chemoresistance.
2. Autophagy Process and Regulation
The term autophagy encompasses diverse cellular processes that are characterized by lysosomal
degradation of cytoplasmic material. Three different types of autophagy have been described:
Microautophagy, chaperone mediated autophagy (CMA), and macroautophagy [8]. Microautophagy
consists of direct engulfment, via lysosomal membrane invagination, of cytoplasmic material that
has to be degraded [9]. In mammals, this process also occurs in late endosomes, which is known
as endosomal microautophagy [10]. CMA involves the targeting of specific proteins by chaperones
and their delivery to lysosomes for their subsequent degradation [11]. Finally, macroautophagy is a
highly conserved process involving the formation of autophagosomes, double membrane vesicles
that engulf cytoplasmic components and fuse with the lysosomes for their content degradation [2]. A
specific type of macroautophagy is called mitophagy, which consists of the selective degradation of
damaged mitochondria by autophagy, promoting their turnover, and preventing the accumulation of
dysfunctional mitochondria [12].
Macroautophagy (here on called autophagy) has multiple steps, including the initiation, nucleation,
elongation, maturation, and vesicle content degradation (Figure 1). This process is tightly regulated
at the molecular level by a family of proteins called autophagy-related proteins (ATGs) [13]. The
initiation step can be triggered through diverse stresses, such as growth factors or nutrient deprivation,
hypoxia, oxidative stress, and protein aggregation, among others [4]. Under starvation, low levels
of glucose, amino acids, or growth factors provoke the activation of Unc-51-like kinase 1 (ULK1)
complex (consisting of ULK1, ATG13, RB1-inducible coiled-coil protein 1 (FIP200) and ATG101))
through the inhibition of the mammalian target of rapamycin complex 1 (mTORC1) [14,15]. Similarly,
low levels of ATP activate AMP-activated protein kinase (AMPK), inducing mTORC1 inhibition and
subsequent ULK1 activation [16]. Once ULK1 complex is activated (initiation step), it induces the
phosphorylation and activation of the catalytic subunit of vacuolar protein sorting 34 (VPS34), a class
III phosphatidylinositol 3-kinase (PI3KC3) that forms a complex with VPS15, Beclin-1, and ATG14.
During the vesicle nucleation step, Beclin-1 acts as a scaffold for the rest of the components and VPS34
converts phosphatidylinositol (PI) to PI-3-phosphate (PI3P) giving rise to the phagophore, the initial
portion of double membrane that will enclose the cytoplasmic material. This process takes place
in the endoplasmic reticulum by the anchoring of the PI3KC3 complex through ATG14 protein to
a region called omegasome [17]. After phagophore formation, ATG7 and ATG10 mediate ATG12
conjugation to ATG5, which form a complex with ATG16L1 that attaches to to the autophagosome
membrane during vesicle elongation. At the same time, microtubule-associated protein light chain 3
(LC3, also named ATG8) is cleaved by the protease ATG4 to form LC3-I, then it is activated by ATG7
and finally ATG3, at the vesicle membrane, promoting the conjugation of LC3-I (or γ-aminobutiric
acid receptor-associated proteins (GABARAPs)) with membrane-resident phosphatidylethanolamine
(PE) to form LC3-II that will permit cargo recognition and vesicle elongation and fusion [18,19]. Apart
from the endoplasmic reticulum, other compartments also act as membrane donors, such as Golgi,
recycling endosomes, mitochondria, or plasma membrane [20,21]. After vesicle expansion and sealing,
the autophagosome maturates and fuses with the lysosome, resulting in an autophagolysosome.
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Several soluble N-ethylmaleimide-sensitive factor activating protein receptor (SNARE) proteins, such
as syntaxin 17 (STX17) and synaptosomal-associated protein 29 (SNAP29) or the lysosome-associated
membrane protein 2 (LAMP2) participate in the fusion of autophagosomes with lysosomes [22,23].
Finally, acidic hydrolases coming from the lysosome degrade the autophagic cargo and the resulting
products, such as amino acids or fatty acids, are finally recycled to the cytosol.
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Figure 1. Mechanism of autophagy. The phases of the process of autophagy (nucleation, elongation,
maturation, and degradation), with the main proteins that participate in each one, are depicted.
Autophagy activators (green) and inhibitors (red) are marked where they interfere with the autophagy
process. Numbers correspond to those compounds listed in Tables 1 and 2, respectively.
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3. Dual Role of Autophagy in Cancer
Autophagy has opposing roles in cancer, preventing tumor initiation in healthy tissues, but
favoring cancer progression once the tumor is formed [4]. Before the onset of carcinogenesis, the
cytoprotective role of autophagy has been described to mainly act as a tumor suppressor mechanism,
mitigating metabolic stress and genome instability that may cause tumor initiation [24,25]. Indeed,
loss of function of ATGs, such as Beclin-1, has been associated with increased risk of cancer [26,27].
For instance, the suppression of ATG proteins in mice has been shown to provoke multiple benign
tumors in liver [28]. However, once the primary tumor is formed, the role of autophagy in cancer cells
varies, being cytotoxic or cytoprotective depending on the cellular context [7]. Therefore, it is crucial
to understand the dual role of autophagy in cancer cells for the selection of a successful therapeutic
strategy targeting autophagy.
On one hand, some tumors can undergo autophagic cell death (ACD) upon the induction of
autophagy by some anticancer drugs, acting as a cytotoxic process [29,30]. ACD frequently occurs
in cancer cells lacking functional apoptotic machinery, such as p53-deficient cancer cells [31]. Hence,
autophagy induction may be an appropriate therapeutic strategy for this type of tumors. Likewise,
autophagy activation has also been described as beneficial when combined with therapies that induce
immunogenic cell death, since cells dying from autophagy release certain molecules, damage-associated
molecular pattern molecules (DAMPs), which recruit immune effectors enhancing the therapeutic
response [8,32,33].
On the other hand, some tumors trigger autophagy as a response to mitigate the cellular stress
induced by an anticancer drug. In this case, inhibition of autophagy sensitizes cancer cells to therapy,
enhancing the cytotoxic effects induced by chemotherapeutic agents [34–37]. Indeed, autophagy has
been described as a pro-survival mechanism present in most advanced tumors, facilitating tumor
adaptation to different stresses, such as hypoxia or nutrient deprivation, thus mediating tumor
progression [38,39]. Accordingly, many types of advanced cancers show higher basal autophagic
activity than normal tissues, and some have been described as “autophagy-dependent” tumors, such
as pancreatic cancer or activated Ras tumors [40,41]. This basal autophagy also facilitates cancer cell
adaptation to therapy-induced stresses, provoking therapy resistance in these tumors, which is one
of the major challenges in the clinic. Moreover, autophagy has also been related to the survival of
dormant cancer cells and metastatic tumor recurrence [42]. Hence, the inhibition of autophagy may be
an appropriate therapeutic strategy to treat these tumors.
4. Therapeutic Strategies Targeting Autophagy
Modulation of autophagy has emerged as a promising therapeutic option for cancer treatment.
Due to the dual role of autophagy in cancer cells, activators as well as inhibitors have been described
as feasible chemotherapeutic agents.
In this section, we compiled different therapeutic interventions targeting autophagy, either for its
stimulation or for its inhibition (Figure 1).
4.1. Autophagy Stimulation for Cancer Treatment
Induction of ACD has become an interesting alternative to overcome resistance to apoptosis and
to exploit a caspase independent cell death for cancer treatment. In the following sections, compounds
for which the mechanism of action is based on stimulating autophagy are described (Table 1).
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Table 1. Autophagy activators.
Mechanism of Action/Type Name Structure Number in Figure 1 Refs.
mTOR Inhibitors
Rapacmycin
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4.1.1. mTOR Inhibitors
The mTOR is a protein kinase that participates in multiple cellular processes such as cell growth,
survival, metabolism, and immunity. Thus, mTOR regulates several cellular mechanisms including
cell cycle, apoptosis, and autophagy [74], inhibiting the initiation of the latter process [75]. Rapamycin
(sirolimus), a secondary metabolite isolated from Streptomyces hygroscopicus, showed potent antifungal,
antitumor, and immunosuppressive properties [76,77]. Rapamycin and its semi-synthetic analogues,
known as rapalogs, are allosteric selective inhibitors of mTORC1 affecting downstream targets,
including the activation of autophagy [78,79]. However, their efficacy inhibiting tumor growth is
limited due to lack of inhibition of mTORC2 and other compensatory signaling pathways that promote
cell survival [80].
Rapamycin has shown to inhibit proliferation and induce ACD in murine sarcoma [43],
neuroblastoma [44], lung cancer [45], and osteosarcoma [46]. Conversely, the rapalog temsirolimus
or cell cycle inhibitor-779 (CCI779), has shown to inhibit tumor growth in vitro in adenoid cystic
carcinoma [47] but has also shown to stimulate autophagy as a pro-survival mechanism in renal-cell
carcinoma [48]. Additionally, everolimus (or RAD001), a derivative rapalog developed for oral
administration, has shown to induce cell cycle arrest through autophagy-mediated degradation of
cyclin D1 in breast cancer cells [49], but promotes autophagy in aromatase inhibitor-resistant breast
cancer cells as a mechanism of resistance [50].
Other types of mTOR inhibitors are compounds that compete with ATP, impeding phosphorylation
of its target proteins, resulting in a more efficient inhibition of mTOR [81]. Among them, AZD8055
inhibits both mTOR complexes and has shown to inhibit tumor growth [51] and induce ACD in
hepatocellular carcinoma cell lines [52], but it is also capable of limiting tumor growth through
induction of apoptosis and cell cycle arrest [82]. Taken together these findings suggest that mTOR
inhibitors may act through different mechanisms to induce cell death in a tumor context dependent
manner, which makes them suitable for combined therapies to overcome cancer cell resistance [83].
4.1.2. BH3 Mimetics
BH3 (Bcl-2 homology 3) mimetics are a group of small molecules that mimic interactions of
BH3-only proteins [84], which are a sub-group of pro-apoptotic proteins in the Bcl-2 family [85].
In general, BH3 mimetics may stimulate autophagy by liberating Beclin-1 from Bcl2 and Bcl-XL
inhibition [85,86].
Gossypol is a BH3 mimetic isolated from cotton that has a high affinity for Bcl-2, Bcl-XL, Mcl-1,
and Bcl-w [85]. Its orally available enantiomeric form (-)-gossypol (AT-101) has shown to induce ACD
in malignant glioma [56], but the induced autophagy has also been accompanied by apoptosis in head
and neck squamous cell carcinoma [53], malignant mesothelioma [54], and colon cancer cells [55].
Obatoclax (GX15-070) is another BH3 mimetic that has shown autophagic-mediated necroptosis in
oral squamous cell carcinoma [57], rhabdomyosarcoma cells [58], and acute lymphoblastic leukemia
cells [59]. Moreover, obatoclax induced autophagy in adenoid cystic carcinoma [87] and Beclin-1
independent autophagy inhibition in colorectal cancer cells [88]. Finally, ABT-737 has shown effectivity
in vitro for hepatocellular carcinoma cells in a Beclin-1-dependent autophagy manner [60].
4.1.3. Cannabinoids
Cannabinoids are a group of more than 60 lipophilic ligands for specific cell-surface cannabinoid
receptors (CB1 y 2) present in the plant cannabis sativa, with ∆9-Tetrahydrocannabinol (THC)
being the main psychoactive compound [89]. Cannabinoids have shown potent anticancer effects
related to autophagy, but they have also shown cytoprotective effects depending on cell type and
cannabinoid used [90]. THC has shown to activate non-canonical autophagy-mediated apoptosis in
melanoma cells [61] and induce ACD in glioma cells through mTORC1 inhibition and autolysosome
permeabilization with the consequent release of cathepsins and posterior induction of apoptosis [62,63].
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JWH-015 is a synthetic cannabinoid CB2 receptor-selective agonist that has shown to inhibit tumor
growth through an autophagy-dependent mechanism in hepatocellular carcinoma cells and in vivo
models through inhibition of Akt/mTORC1-pathway via AMPK activation [64].
4.1.4. Histone Deacetylase Inhibitors (HDACIs)
The HDAC family includes four classes (I-IV) of transcriptional repressors that alter the structure
of chromatin (via deacetylation) [91] and have been studied as anticancer compounds based on their
potential to regulate gene expression [92]. Although apoptosis has been referred to as the main route
for HDACIs-induced cancer cell death, autophagy stimulation has also been implicated, being the
inactivation of PI3K/Akt/mTOR signaling the most described pathway [93].
Suberoylanilide hydroxamic acid (SAHA, Vorinostat) (a pan HDAC inhibitor) was the first HDACI
approved by the FDA for the treatment of cutaneous T-cell lymphoma [94] that has shown to inhibit
tumor growth through autophagy stimulation via activation of Cathepsin B in breast cancer cells
in vitro [65]. Finally, MHY2256 (a synthetic class III HDAC inhibitor) has shown to induce ACD, cell
cycle arrest and apoptosis in endometrial cancer cells in both in vitro and in vivo [66].
4.1.5. Natural Products
Some natural compounds have shown promising anticancer activities based on autophagy
stimulation. Betulinic acid is a pentacyclic triterpenoid derived from widespread plants that has
shown to induce ACD in multiple myeloma cells with high levels of Bcl-2 expression. This derivative
acts as an attenuator for mitochondrial-mediated apoptosis, promoting ACD by inducing Beclin-1
phosphorylation [67]. Resveratrol, a polyphenol compound widely found in plants, has been shown to
inhibit cell proliferation in breast cancer stem-like cells via suppressing the Wnt/b-catenin signaling
pathway [68]. This pathway, which regulates critical genes in tissue development and homeostasis, is
aberrantly activated in many cancers and its inhibition has been reported to be related with autophagy
processes [68,95]. δ-Tocotrienol is one of the four isomers that comprises vitamin E that has shown
cytotoxic effects against prostate cancer cells in vitro through autophagy activation via ER stress [69].
Curcumin is a major constituent of Curcuma longa (turmeric) that induces autophagy, which has been
shown to elicit a dual role protecting or leading to cell death depending on the duration of the treatment
and concentration used [70].
4.1.6. Others
Other compounds have been reported to induce ACD in cancer. For example, lapatinib is a small
molecule tyrosine kinase inhibitor, targeting epidermal growth factor receptors that is capable of
inducing ACD in hepatocellular carcinoma [71] and in acute leukemia cell lines [72]. APO866 is an
inhibitor of nicotinamide adenine dinucleotide (NAD) biosynthesis that has shown anticancer activity
through induction of ACD in cells from hematological malignancies [73].
4.2. Autophagy Inhibition for Cancer Treatment
In several tumors, autophagy has a protective role; therefore, its inhibition could be an interesting
approach for tumor treatment. There are several autophagy inhibitors that block the process of
autophagy at different steps, which we detail below (Table 2).
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Table 2. Autophagy inhibitors.
Mechanism of Action Name Structure Number inFigure 1 Refs.
ULK Inhibitors
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4.2.1. ULK Inhibitors
ULKs are a family of serine/threonine protein kinases that form complexes with multiple regulator
units. The role of ULK1 is essential for the initiation of autophagy [15,160,161], however the role of
ULK2 in autophagy seems to be cell type dependent [162]. Due to the homology between ULK1 and
ULK2 [163], inhibitors of ULK1 also inhibit ULK2 [163]. ULK1 has been shown to be upregulated in
several cancers, which correlated with poor prognosis and treatment resistance [99,164–166]. Inhibition
of ULK1 has been shown to induce a decrease in tumor growth and induction of apoptosis [100,101].
This has led to the search for compounds that inhibit this kinase activity finding some molecules
that compete with the ATP-binding site, such as compound 6 [96], MRT68921, and MRT67307 [97,98].
Besides them, SBI-0206965 is the most studied [102], which inhibits autophagy and induces apoptosis
in neuroblastoma cell lines [100], non-small cell lung cancer (NSCLC) cells [101,102], and in clear cell
renal carcinoma cells [99]. Moreover, it has also been reported to be a direct inhibitor of AMPK, which
is a serine/threonine kinase that activates the ULK complex, among other roles [167]. Recently more
ULK inhibitors, such as ULK100 and ULK101, have been described [103], which supports that the idea
that blocking ULK1 may be a good strategy for cancer therapy.
4.2.2. Pan PI3K Inhibitors
The family of phosphoinositide 3-kinases (PI3Ks) is divided into three classes with different
substrate preferences, which define their functions. The role of class II on autophagy is unclear. However,
class I activates mTORC1 through the PI3K/Akt pathway and consequently inhibits autophagy, while
class III (VPS34) activates autophagy [168]. PI3K pathways have been associated with cancer due
to their participation in tumorigenic processes such as cell proliferation, survival, migration, and
angiogenesis. Therefore, they are a good target for therapy development [169]. Most of the studied
PI3K inhibitors are not selective for a specific class of PI3K, hence, they affect different cellular processes,
not only autophagy, and consequently their effect cannot be only attributed to inhibition of autophagy.
However, due to their therapeutic relevance, we describe briefly some of them below.
3-Methyladenine (3MA) was one of the first inhibitors of autophagy described [104]. It exerts
a dual effect on autophagy. Under starving conditions it suppresses autophagy through PI3KC3
inhibition. However, in the presence of nutrients it promotes autophagy by inhibition of PI3KC1 [105].
Additionally, it has been reported that it reduces the expression of drug efflux transporters, overcoming
taxol and doxorubicin resistance [106]. 3MA is effective at high concentrations, although presents
solubility problems. In order to overcome this limitation some derivatives have been synthetized [107].
Wortmannin is a fungal metabolite that binds irreversibly to the catalytic site of PI3Ks [108,109].
LY294002 is a synthetic small molecule [110] with poor solubility and short half-life. A conjugate analog
of LY294002, named SF1126, was designed to accumulate in integrin expressing tissues, improving
LY294002 solubility and pharmacokinetic, favoring its accumulation in the tumor site and showing
antitumor and antiangiogenic properties in mouse models [111,112]. Other non-selective Pan PI3K
inhibitors are PI103 [113], KU55933, Gö6976 [114], and GSK1059615 [115,116,170].
4.2.3. VPS34 (PI3KC3) Complex Inhibitors
VPS34 is a PI3KC3 that transforms PI to PI3P. VPS34 forms a complex with several subunits needed
for its activation, such as VPS15 (also known as p150), ATG14, and Beclin-1. Autophagy can be blocked
by inhibition of VPS34 activity; SAR405 is one compound of the (2S)-tetrahydropyrimido-pyrimidinones
series with kinase inhibitor activity by strong competition for ATP site. However, it is highly selective
for PI3KC3, compared to class I and II, and more than 200 protein kinases and 15 lipid kinases.
SAR405 inhibits autophagy induced either by starvation or mTOR inhibition [113]. VPS34-IN1 is a
bipyrimidinamine that inhibits PI3KC3 selectively, compared with more than 300 protein kinases
analyzed [117]. Additionally, PIK-III, a bisaminopyrimidine, binds to a hydrophobic pocket unique in
VPS34 that cannot be found in other related kinases [118]. Compound 31 is a small molecule selective
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against protein and other lipid kinases [119]. All these four inhibitors are selective for PI3KC3, but it
should be noted that VPS34 can form different complexes with other subunits that lead to a different
localization and function, participating also in vesicle trafficking [171]. Thus, inhibitors of VPS34 can
also have an effect on endosomal trafficking, as the case of SAR405 that prevents the activity of both
VPS34 complexes [113]. Therefore, it may also affect cellular secretion [172].
On the other hand, autophagy can be also inhibited blocking PI3KC3 complex formation; Spautin-1
indirectly inhibits the activity of VPS34 by proteosomal degradation of proteins that form VPS34
complexes through reduction of Beclin-1 deubiquitination mediated by USP10 and USP13 [120].
4.2.4. ATG inhibitors
Membrane PI3P produced by VPS34 leads to the recruitment of PI3P-binding ATG proteins and
additional factors, resulting in the formation of complexes that participate in the elongation of the
phagophore. Inhibition of autophagy can be achieved by impeding the formation of these complexes.
ATG7 participates in the formation of the complex ATG12-ATG5 and the conjugation of PE to
LC3 and GABARAP. Recently, some inhibitors of ATG7 (WO2018/089786) have been designed and it
has extended the use of micro RNAs that target ATG7 gene such as miR-154 that inhibits blade cancer
progression [121].
On the other hand, ATG4B cleaves LC3, activating it for its conjugation with PE [173] necessary
for the expansion of the autophagosome and its recognition. Additionally, it participates in LC3-PE
deconjugation, which is important for LC3 recycling and for the fusion of the autophagosome with the
lysosome [174]. Therefore, ATG4B could be a good target to inhibit autophagy more selectively, thus,
a large number of ATG4B possible inhibitors have been screened in the last years [175]. NSC185058
is a small compound that docked at the active site of ATG4B inhibiting not only autophagy but also
the volume of the autophagosomes, which is accompanied by suppression of tumor growth in an
osteosarcoma subcutaneous mouse model [122]. Tioconazole is an antifungal drug that binds to the
active site of ATG4 blocking autophagy flux reducing cell viability and sensitizing tumor cells to
doxorubicin in a xenograft mouse model [123]. Other ATG4B inhibitors that suppress autophagy in
cell lines and in vivo inhibiting cell proliferation are UAMC-2526, a derivative of benzotropolones
stable in plasma [124], and LV-320, a styrylquinoline [125].
It should be noticed that the roles of ATG4B in cancer are not well understood and some of
the ATG4 inhibitors showed only inhibition in LC3-PE delipidation, but not in the autophagosome
formation such as S130 [126] and FMK-9a [127–129]. Additionally, some studies are focused on the
evaluation of different markers that may predict the effectiveness of those inhibitors [176]. For instance,
ATG4B inhibition is effective only in Her-2 positive cells and not in those negative [177].
4.2.5. Autophagosome Formation Inhibition
Verteporfin is a benzoporphyrin derivative used in the clinic in photodynamic therapy.
Interestingly, it prevents autophagosome formation induced by glucose and serum deprivation,
but not by mTOR inhibition [130]. One possible mechanism of action of verteporfin is the
blockade of p62 oligomerization, a protein necessary for the sequestration of ubiquitinated targets
into autophagosomes [178,179]. Additional to autophagy inhibition, verteporfin reduces [131,133]
transcriptional co-activators that regulate the Hippo pathway, implicated in cell growth and stem
cell function [180]. Verteporfin inhibits cell proliferation, angiogenesis, and migration, and induces
apoptosis [181]. It inhibits autophagy in vivo but has no effect as a single agent in tumor growth.
However, it moderately sensitizes tumor cells to cytotoxic agents [132].
4.2.6. Lysosome Inhibitors
The last step in autophagy is the fusion of autophagosomes with lysosomes, whose hydrolases
degrade the autophagosome content. The inhibition of autophagy at this point consists of the use of
lysosomal inhibitors.
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Chloroquine (CQ) and its analog hydroxychloroquine (HCQ) [136] are drugs used for the treatment
of various diseases, such as malaria and more recently cancer [135]. They are weak bases and the
unprotonated form of CQ/HCQ can diffuse through cell membranes and enter into organelles such as
lysosomes, where the high concentration of H+ induces their protonation and consequently increases
lysosomal pH [134]. Once CQ/HCQ are protonated, they are trapped in the lysosomes producing an
increase of their volume, and inhibiting the activity of lysosomal enzymes.
CQ and HCQ are the only autophagy inhibitors approved for clinical use. Although short-term
CQ/HCQ treatment has been considered safe, retinopathy has been reported produced by long-term
treatment with HCQ in about 7.5% of patients [182] and cardiotoxicity [183]. The prevalence depends on
the dosage and the duration of treatment [184]. This toxicity limitation, along with inconsistencies in the
results obtained in the clinic, have led to the study of new and more potent autophagy inhibitors [185].
Thus, CQ analogs that exert more potent autophagy inhibitory activity have been synthetized. Lys05
is a dimeric analog of CQ that accumulates within acidic organelles, including lysosomes, more
potently than HCQ [137]. DQ661, a dimeric quinacrine (DQ), not only inhibits lysosomal catabolism,
including autophagy, but also targets palmitoyl-protein thioesterase-1, resulting in the inhibition of
mTORC1 signaling. DQ661 has shown effects on tumor mouse models alone and it also overcame
resistance to gemcitabine [139]. Another antimalaria compound found to inhibit autophagy with
antitumoral properties is VATG-027 [140]. On the other hand, mefloquine is also accumulated in
lysosomes disrupting autophagy, it induces apoptosis and inhibits multidrug resistance protein1
(MDR1) being effective in multidrug-resistant tumor cells [142]. Mefloquine sensitizes chronic myeloid
leukemia (CML) cells derived from patients in chronic phase to TK inhibitors showing selectivity for
stem/progenitor tumoral cells to normal cells [141].
CQ and its derivatives are not the only drugs that target lysosomes to inhibit autophagy; GLP
(ganoderma lucidum polysaccharide) is a polysaccharide from the fungus Ganoderma lucidium with
multiple antitumoral properties [143]. GLP induces apoptosis in cancer cell lines [145] and reduces
tumor growth in mouse models [144]. It has recently been seen that GLP impairs autophagy flux by
reduction of lysosome acidification and the accumulation of autophagosomes has suggested to be
the cause of apoptosis induction [144]. Bafilomycin A (BafA) is a vacuolar-H+ ATPase inhibitor that
disrupts the acidification of lysosomes, vesicles, and vacuoles [146,147] by preventing the entry of H+
into these organelles. BafA also inhibits the fusion of autophagosomes with lysosomes, by disruption
of Ca2+ gradients implied in this process [148].
Ionophores can also disrupt lysosomal pH, impairing the autophagy process. Tambjamine
analogues are anion selective ionophores derived from the naturally occurring tambjamines and induce
mitochondrial swelling and autophagy blockade with cytotoxic effects in lung cancer cells and cancer
stem cells (CSCs) [149]. Monensin, nigericin, and lasalocid are cation ionophores, but only monensin
presents selectivity for lysosomes [150]. Squaramides are synthetic chloride transporters that also
induce cell death by apoptosis [151].
On the other hand, the WX8-family comprises five chemical analogs that disrupt the fusion of
lysosomes with autophagosomes, lysosomes fission, and sequestration of molecules into the lysosomes
without altering their pH. These compounds bind to PIKFYVE phosphoinositide kinase and present
potent antitumoral effects on autophagic dependent cells [152]. Vacuolin-1 activates RAB5A blocking
the fusion of the autophagosomes with lysosomes, however it also inhibits the fusion of endosomes
with lysosomes, resulting in a general endosomal-lysosomal degradation defective [153].
Clomipramine (CM) is a FDA-approved prodrug for the treatment of psychiatric disorders the
metabolite of which, desmethylclomipramine (DCMI), impairs autophagic flux blocking lysosomal
degradation that sensitizes tumor cells to cancer treatment [154]. DCMI also affects lung CSCs [186].
Additionally, protease inhibitors can also inhibit the lysosomal degradation, such as pepstatin A
(aspartyl proteases; cathepsin D and E), Leupeptin [155] and E64d (cysteine proteases; cathepsin
B, H, and L) [156]. On the other hand, nanoparticles are usually accumulated into lysosomes by
endocytosis internalization, which may cause lysosome impairment [157]. Gold nanoparticles [158]
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and nanodiamonds have shown to inhibit autophagy by disruption of lysosomal function, which
sensitizes tumors to arsenical base therapy [159].
Several studies have suggested that the anti-tumor effects of lysosomal inhibitors may be
independent of autophagy inhibition since they also interfere in other cellular mechanisms producing
non-autophagy related effects [187–194]. Remarkably, disruption of the lysosomes not only blocks
autophagy, but lysosomal permeabilization releases proteases such as cathepsins that are active at
cytosolic pH and participate in apoptosis and apoptosis-like and necrosis-like cell death [195–197].
Additionally, lysosomes also participate in tumor invasion, hence, these inhibitors have shown to be
effective against metastasis [138,198–200], targeting cancer stem cells [201], and inducing tumor vessel
normalization [202].
As mentioned above, there are efforts to find genetic determinants to sensitivity or resistance
to these lysosomal inhibitors. Metastatic cells are more vulnerable to CQ and BafA, suggesting that
patients with metastasis could benefit from those treatments [198]. Morgan and coworkers also showed
a relationship between the expression of ID4 and metastatic potential. Additionally, overexpression
of helicase-like transcription factor (HLTF) seems to be related with the resistance to HCQ, Lys05
and BafA treatment [189] and tumors with the V600E mutation in BRAF (v-Raf murine sarcoma viral
oncogene homolog B) present cytoprotective autophagy [203].
5. Autophagy Modulation for Tumor Sensitization to Anticancer Therapies
It has been accepted that chemotherapy, as well as radiotherapy, could activate autophagy.
This opens the possibility that modulation of autophagy may enhance sensitivity to these cancer
treatments [204]. In this section, we highlight some combination therapies that use compounds that
target autophagy-inducing sensitization of cancer cells to anticancer therapies.
5.1. Autophagy Modulation to Overcome Radio-Resistance
One of the first-line treatments for many types of cancers is radiotherapy. The combination
of autophagy inhibitors and radiation therapy has shown improved anti-tumor effects in cancer
treatment. For instance, the ATG4B inhibitor NSC185058 [205] and CQ enhance the antitumor effect
of radiotherapy in glioblastoma. Furthermore, non-cytotoxic amounts of CQ enhanced the radiation
sensitivity in bladder cancer cell lines [206].
The activation of autophagy also radiosensitizes the cells [207] and this effect is increased
in the presence of apoptosis inhibitors [208]. Thus, combination therapies based on autophagy
stimulation have been formulated to overcome radioresistance in some tumors. For example, YCW1,
an optimized HDACI, enhances radiosensitivity in breast cancer cells inducing ER stress and increasing
autophagy [209]. Similar results have been reached using a combination of radiotherapy, THC, and
cannabidiol in glioma [210] and gossypol in glioblastoma multiforme [211].
As mentioned before, the effect of autophagy after radiation is not uniform in all types of
tumors; it can be cytoprotective, non-cytoprotective, or have a cytotoxic effect [212]. Hence, the
efforts should be focused on the determination of some markers that could predict the effect of
autophagy modulators in combination with radiotherapy. For instance, the expression of p53 has
been suggested to be determinant for a radiosensitization effect of CQ [213] and p18-CycE (proteolytic
cyclin E fragment) [214]. Nrf2 antioxidant pathway seems to be involved in autophagy-induced
radioresistance, which is reversed by 3MA co-treatment [215]. Phosphatase and tensin homolog
deleted on chromosome 10 (PTEN) loss is associated with radio and chemoresistance, and activation of
autophagy by rapamycin induces cytotoxic autophagy that overcomes radioresistance [216].
It should be noted that the models used to analyze these radiosensitization effects are of major
importance in order to obtain feasible results. For instance, inhibition of autophagy combined with
radiotherapy in immunodeficient mice has a sensitization effect; however, in immunocompetent
mice it promotes tumor growth. [217]. This opposite effect is due to the role of autophagy in the
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immunogenic antitumor response [218]. Therefore, these types of studies should be performed in an
immunocompetent context.
5.2. Autophagy Modulation to Overcome Chemoresistance
Inhibition of autophagy may sensitize tumor cells to common drugs or may overcome the
resistance acquired by those cells to chemotherapeutic agents [219]. In this section, we highlight some
of the most recent and relevant findings in combining different antitumor drugs with autophagy
inhibitors and some activators.
CQ and HCQ potentiate the cytotoxicity of multiple drugs such as 5-fluorouracil [220],
cisplatin [221], and temozolomide [222,223]. Moreover, combination treatment with CQ and
trastuzumab completely suppressed tumor growth by >90% in a HER2-positive breast cancer tumor
xenograft completely refractory to trastuzumab [224].
Additionally other autophagy inhibitors have shown interesting results; verteporfin increased
the potential of gemcitabine in an in vitro model of pancreatic cancer [109]. SBI-0206965 overcame
resistance to cisplatin in NSCLC cells [101] and to cabozantinib in metastatic colorectal cancer [225].
The combination of celecoxib, a specific inhibitor of cyclooxygenase-2, with CQ and SAR405 resulted in
higher cell death [226], and 3MA also enhanced cell death induced by bortezomib in glioblastoma cell
lines [227]. Moreover, the combination of the CQ analog lys05 with the second generation of tyrosin
kinase inhibitor, nilotinib, has shown an additive effect in the reduction of the number of leukemia
stem cells in CML mouse models [138]. UAMC-2526 potentiates the effect of oxaliplatin in colorectal
cancer xenograft mouse model by inhibition of autophagy, and tumors treated with UAMC-2526 also
showed a more differentiated phenotype [124].
The combination of autophagy activators and inhibitors together have also been studied; CQ
and HCQ potentiate the effect of mTOR inhibitors, such as temsirolimus [228] or everolimus in
colorectal cancer cells [229], melanoma [228], and neuroendocrine neoplasms [230], showing inhibition
of autophagy as a mechanism to overcome resistance to mTOR inhibitors. In addition, CQ has also
demonstrated to improve anticancer effects of vorinostat [231], as well as a combination of everolimus
and SAR405 showed synergy [113,232]. These results would make one think that the inhibition of
autophagy is a better therapeutic approach because autophagy presents a protective role in these models.
However, although to a lesser extent, autophagy activators are also able to overcome chemoresistance.
Temsirolimus has demonstrated to potentiate the activity of gemcitabine and cisplatin in bladder
cancer cell lines [233] and also decrease the resistance of colon cancer cells to cetuximab [234]. Similarly,
curcumin has shown to enhance gefitinib effect on primary gefitinib-resistant small-cell lung cancer
cells through an autophagy-dependent synergism [235].
Nevertheless, in some cases, autophagy modulation has shown controversial results in preclinical
studies. For instance, it has been shown in vitro that SBI-0206965, an ULK1 inhibitor, induces apoptosis
in combination with mTOR inhibitors in A549 cells [100,102]. However, in neuroblastoma cells,
SBI-0206965 sensitizes cells to TNF-Related Apoptosis Inducing Ligand (TRAIL) treatment but not to
mTOR inhibitors [100] indicating the non-protective role of autophagy in this model. At this point,
it would be necessary to use molecular markers that could predict the response of the tumors to
autophagy modulators, such as v-Raf murine sarcoma viral oncogene homolog B (BRAF) V600E
mutation, which has been associated with protective autophagy [236].
Finally, the development of nanotechnology exploits tumor-targeting therapy directing multiple
drugs to the tumor mass, including autophagy inhibitors, which have been encapsulated in different
nanocarrier systems to obtain more efficient therapies. On one hand, HCQ nanoencapsulation showed
more efficacy than free HCQ [237,238]. On the other, these multiplatform systems allow the combination
of autophagy inhibitors with other chemotherapeutic agents [239–241], diagnosis system [237], or
other therapeutic approaches, such as sonodynamic [242] or photothermal therapy, showing efficient
tumor suppression effect [243,244]. Additionally, CQ may be used to promote the accumulation of
the drugs in the tumor site; pretreatment with CQ affects macrophages endocytic capacity, which
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limits nanoparticle accumulation in the liver, reducing liver clearance [245], and improves tumor
microcirculation, which promotes co-delivery of antitumoral drugs in tumors [246].
All of the above suggest that modulation of autophagy may be a promising approach to overcome
radio and chemoresistance. However, more efforts are needed to predict the response of patients to
those treatments.
6. Combination Therapy in Clinical Trials
Inhibition and activation of autophagy for cancer treatment has been evaluated in the clinic and
clinical trials with autophagy modulators that present results are compiled in Table 3.
CQ and HCQ have been included in 21 and 66 clinical trials for cancer treatment, respectively, 17
of which are currently active and 24 have been completed [6]. In summary, HCQ has limited activity
as a single agent, despite the fact that it inhibits autophagy in patients with different early-stage
solid tumors [247]. However, the analysis of autophagy in patients with metastatic pancreatic
adenocarcinoma showed inconsistent inhibition and no significant therapeutic efficacy [248]. The
inhibition of autophagy in combination therapies of HCQ with anticancer agents such as gemcitabine,
temozolomide, and bortezomib has been corroborated. However, efficacy results with these and other
chemotherapeutic agents, such as erlotinib, were negligible [249] or moderate [250,251]. Additionally,
the combination of HCQ with chemotherapy and radiotherapy at the same time inhibited autophagy in
45–66% of patients and this combination did not improve the overall survival rate [252]. Patients with
glioblastoma that had received radiotherapy and chemotherapy were treated for 12 months with CQ
showing limited results [253]; however, chronic administration of CQ improved the overall survival
rate about 50% [254]. Additionally, the combination of radiotherapy with CQ did not improve the
overall response rate in patients with brain metastasis [255].
All these results show inconsistency not only at the level of autophagy inhibition but also in the
efficacy outcome of this therapy. As mentioned before, the role of autophagy is context dependent,
and this has been proven in the clinic. For instance, CQ overcame resistance to vemurafenib, a
BRAF inhibitor, in different patients with BRAFV600E-mutant brain tumors [203,256]. However, this
combination showed no synergistic effect on patients without this mutation [203]. This points out the
importance of the identification of patients that are most likely to respond to this combination therapy.
Regarding autophagy activators, (-)-gossypol in combination with cisplatin and etoposide has
shown promising results on phase I clinical trial for small cell lung cancer [257]. However, its
combination with docetaxel or androgen deprivation therapy have not demonstrated enough efficacy
on phase II clinical trial for head and neck cancer [258] or metastatic prostate cancer [259]. Vorinostat
in combination with tamoxifen showed moderate response with 40% of response or stable disease in
patients with hormone-therapy resistant breast cancer [260].
Finally, the combination of autophagy activators and inhibitors, such as the combination of
vorinostat with HCQ has shown promising results [261]. Although rapalog temsirolimus is not
powerful enough to be used as a single agent for the treatment of breast and renal carcinoma [262], the
combination of HCQ with rapamycin showed a moderate positive response [263]. Moreover, HCQ
combined with rapamycin in metronomic chemotherapy showed encouraging results with 40% of
partial response and 84% control of disease [264]. Finally, combination of HCQ and temsirolimus
also showed stabilization of the disease in 67–74% of the patients with a consistent inhibition of
autophagy [265].
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Table 3. Clinical trials results with autophagy modulators. Autophagy modulator column has been added.
Clinicaltrials.Gov ID Treatment (Dose Per Day) Autophagy Modulator Condition Study Phase Result Refs.
NCT01273805 HCQ (1200 mg) Inhibitor Metastatic Pancreaticcancer II Lack of efficacy [248]
HCQ (800 mg) Inhibitor Early stage solid tumors I Autophagy inhibition,apoptosis [247]
NCT00771056 HCQ (400 mg) Inhibitor B-cell chroniclymphocytic leukemia II
50% efficacy. No adverse
events
HCQ (1200 mg) + bortezomib Inhibitor Myeloma I Autophagy Inhibition.Moderate response [251]
NCT00786682 HCQ (400 mg) + docetaxel Inhibitor Prostate cancer II Terminated; lack of efficacy
NCT01649947 HCQ (400 mg) + Paclitaxel +Carboplatin + Bevacizumab Inhibitor NSCLC II
Evaluation of Bevacizumab
addition to the drug cocktail
NCT01026844 HCQ (1000 mg) + Erlotinib Inhibitor Advanced NSCLC I Safe but low efficacy [249]
NCT00977470 HCQ (1000 mg) + Erlotinib Inhibitor Advanced NSCLC II Not completed; lack of efficacy
NCT01978184 HCQ (1200 mg) +Gemcitabine + paclitaxel Inhibitor Pancreatic cancer II Moderate results [266,267]
NCT01128296 HCQ (1200 mg) +Gemcitabine Inhibitor
Pancreatic cancer (stage
IIb III) I–II 65% Autophagy inhibition [268]
NCT00486603 HCQ (600 mg) +Temozolomide + radiation Inhibitor Glioblastoma multiforme I–II
Autophagy inhibition in
45–66%. 70% affected by
serious adverse effects.
Lack of efficacy
[252]
HCQ (1200 mg) +
Temozolomide Inhibitor
Advanced solid tumors
and melanoma I
Autophagy inhibition.
Moderate results [250]
NCT01842594 HCQ (400 mg) + Rapamycin Inhibitor + Inducer Sarcoma II Terminated; 60% partialresponse. [269]
NCT01687179 HCQ (400 mg) + Rapamycin Inhibitor + Inducer Lymphaglioleiomyomatosis I Well tolerated. Limitedresponse [263,270,271]
HCQ (1200 mg) +
Temsirolimus Inhibitor + Inducer
Advanced solid tumors
and melanoma I
Well tolerated, autophagy
inhibition. Moderate response [265]
HCQ (600 mg) + Vorinostat Inhibitor + Inducer Advanced solid tumors I Well tolerated, moderateresponse [261]
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Table 3. Cont.
Clinicaltrials.Gov ID Treatment (Dose Per Day) Autophagy Modulator Condition Study Phase Result Refs.
HCQ (400 mg) + Rapamycin
+ metronomic conventional
chemotherapy
Inhibitor + Inducer Solid tumors I Encouraging results [264]
CQ (150 mg) Inhibitor GBM II Encouraging results [185]
CQ (150 mg) + Carmustine Inhibitor GBM Limited response [253]
CQ (250 mg) + radiotherapy Inhibitor GBM Pilot Encouraging results (5patients) [272]
NCT01894633 CQ (150 mg) + radiotherapy Inhibitor Brain metastais II Limited response [255]
CQ (250 mg) + radiotherapy Inhibitor Brain metastasis Pilot Well tolerated [273]
CQ (150 mg) + vemurafenib Inhibitor BRAFV600E Brain tumor
Encouraging results (6
patients) [203,256]
NCT00365599 Vorinostat (400 mg) +Tamoxifen Inducer
hormone-therapy
resistant breast cancer II Moderate response [260]
(-)-gossypol (80 mg) +
cisplatin + etoposide Inducer SCLC I Encouraging results [257]
(-)-gossypol (80 mg) +
docetaxel Inducer Head and neck cancer II Lack of efficacy [258]
NCT00666666
(-)-gossypol (20 mg) +
androgen deprivation
therapy
Inducer metastatic prostate cancer II Lack of efficacy [259]
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7. Conclusions
Targeting autophagy for cancer treatment seems to be a promising therapeutic strategy, although
significant challenges remain to be addressed in order to improve the therapeutic results obtained in
the clinic. In particular, since the outcome of modulating autophagy depends on the tumor context,
it must be carefully defined which patients would benefit from which treatment before starting any
therapeutic intervention.
Autophagy suppresses tumor initiation in healthy tissues, showing a cytoprotective role. Hence,
the modulation of autophagy through autophagy activators might be beneficial in patients with
an increased risk of developing cancers. On the other hand, once the tumor is formed, activating
autophagy will induce ACD in some tumors, provoking their reduction. This strategy may be especially
relevant in apoptosis-resistant tumors. Nevertheless, autophagy has a protective role in other tumors,
especially those called “autophagy-dependent”; hence, the inhibition of autophagy would induce
therapeutic effects in those patients. Indeed, inhibition of autophagy at early or late stages leads to
different consequences; prevention of the autophagosome formation may neutralize the protective
role of autophagy, sensitizing cells to chemotherapeutic agents, being a good strategy for combination
regimens. Conversely, lysosomotropic agents produce autophagy vacuoles accumulation, leading to
cellular stress and a consequent cytotoxic effect, being able to reduce the tumor in single therapy.
This review underscore the double-edged-sword role of autophagy in cancer; hence, a deeper
understanding on how autophagy affects cancer progression, the search of appropriate biomarkers to
identify the responder patient population to a defined autophagy modulator, and clear and suitable
pharmacodynamic markers to monitor patients’ responses are eagerly needed to improve success in
clinical studies with autophagy modulators.
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Abbreviations
ACD autophagic cell death
AMPK AMP-activated protein kinase
ATG Autophagy-related proteins
ATG16L1 Autophagy-related 16-like protein 1
BafA Bafilomycin A
BH3 Bcl-2 Homology 3
BRAF v-Raf murine sarcoma viral oncogene homolog B
CMA Chaperone Mediated Autophagy
CB1 y 2 Cannabinoid receptor 1 y 2
CCI779 Cell Cycle Inhibitor 779
CML Chronic Myeloid Leukemia
CQ Chloroquine
CSC Cancer stem cell
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DCMI Desmethylclomipramine
DQ Dimeric quinacrine
EGFR Epidermal growth factor receptors
ER Endoplasmic reticulum
FIP200 RB1-inducible coiled-coil protein 1
FKBP12 FK506-binding protein 12
GABARAP γ-aminobutiric acid receptor-associated proteins
HCQ Hydroxychloroquine
HDAC Histone deacetylase
HDACIs Histone deacetylase inhibitors
LAMP2 Lysosome-associated membrane protein 2
LC3 Microtubule-associated protein light chain 3
MQ Mefloquine
mTORC1 Mammalian target of rapamycin complex 1
mTORC2 Mammalian target of rapamycin complex 2
PE Phosphatidylethanolamine
PI3K Phosphoinositide 3-kinase
PI3KC1 The class I phosphatidylinositol 3-kinase
PI3KC3 The class III phosphatidylinositol 3-kinase
PtdIns3P Phosphatidylinositol 3-phosphate
ROS Reactive oxygen species
SAHA Suberoylanilide hydroxamic acid
SNAP29 Synaptosomal-associated protein 29
SNARE Soluble N-ethylmaleimide-sensitive factor activating protein receptor
STX17 Syntaxin 17
THC ∆9-Tetrahydrocannabinol
TK Tyrosin Kinase
TOR Target of rapamycin
TRB3 Telomere repeat binding factor 3
ULK (Unc)-51–Like Kinase proteins
VPS15 Vacuolar Protein Sorting 15
VPS34 Vacuolar Protein Sorting 34
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